Role of epigenetic modifyers MBD2 and TET proteins in DNA methylation and demethylation in cancer

表观遗传修饰剂 MBD2 和 TET 蛋白在癌症 DNA 甲基化和去甲基化中的作用

• 批准号: nhmrc : 1029584
• 负责人: Dr Clare Stirzaker
• 金额: $ 48.15万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/role-epigenetic-modifyers-demethylation-cancer/110697
• 关键词: Role; epigenetic; modifyers; MBD2; TET

Cancer is a disease of both genetics and epigenetics, the cell machinery that controls how the DNA code is read. DNA methylation is one part of epigenetics but few studies have investigated how the loss of methylation contributes to cancer formation. We have exciting new data that implicates specific proteins in this process and, with this funding we will determine how these proteins affect gene regulation in cancer, potentially leading to novel cancer diagnosis and treatment strategies.

癌症是一种遗传学和表观遗传学的疾病，表观遗传学是控制DNA代码如何读取的细胞机制。DNA甲基化是表观遗传学的一部分，但很少有研究调查甲基化的丧失如何有助于癌症的形成。我们有令人兴奋的新数据，这些数据涉及这一过程中的特定蛋白质，有了这笔资金，我们将确定这些蛋白质如何影响癌症的基因调控，可能导致新的癌症诊断和治疗策略。